Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
1999
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
2003
Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion
1987
A comparison of manikin CPR performance by lay persons trained in three variations of basic life support guidelines
2000
Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model
2011
Skill mastery in public CPR classes
1998
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
1992
Better adherence to the guidelines during cardiopulmonary resuscitation through the provision of audio-prompts
2005
Retention of basic life support skills 6 months after training with an automated voice advisory manikin system without instructor involvement
2002
Drug-targeting strategies in cancer therapy
2001
Induction of a human carbonyl reductase gene located on chromosome 21
1990
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
2002
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies
2004
Drug penetration in solid tumours
2006 Standout
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
2003
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
2005 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Drug development from marine natural products
2008 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Short-chain dehydrogenases/reductases (SDR)
1995 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Principles of bioactive lipid signalling: lessons from sphingolipids
2008 Standout
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels
2003
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Solid lipid nanoparticles Production, characterization and applications
2001 Standout
Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients
1987
Modulation of multidrug-resistant multiple myeloma by cyclosporin
1992
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion
1993
Polymer conjugates as anticancer nanomedicines
2006 Standout
Targeting multidrug resistance in cancer
2006 Standout
Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy
1989
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
1991
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
2012
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
1995
Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats
2007
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
2001 Standout
PHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)
1999
The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
1994
Congestive heart failure in patients treated with doxorubicin
2003 Standout
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Enhanced Phagocytosis through Inhibition of de Novo Ceramide Synthesis
2003 StandoutNobel
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
2011
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials
2007
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2003 Standout
Quality of Cardiopulmonary Resuscitation During Out-of-Hospital Cardiac Arrest
2005 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid
1992
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Designing dendrimers for biological applications
2005 Standout
Twelve-month retention of CPR skills with automatic correcting verbal feedback
2005
Sphingosine-1-phosphate: an enigmatic signalling lipid
2003 Standout
The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents
1992
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
1995
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
1996
Delivering nanomedicine to solid tumors
2010 Standout
Removal of cytostatic drugs from aquatic environment: A review
2013 Standout
The dawning era of polymer therapeutics
2003 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods
2003
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
Improving survival from sudden cardiac arrest: the "chain of survival" concept. A statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association.
1991 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline
1989
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Tumour stem cells and drug resistance
2005 Standout
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
2001 Standout
Expression of the multidrug resistance associated protein and P- glycoprotein in doxorubicin-selected human myeloid leukemia cells
1994
Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
1992
Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: the Utstein Style. A statement for health professionals from a task force of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, and the Australian Resuscitation Council.
1991 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Functions of Ceramide in Coordinating Cellular Responses to Stress
1996 StandoutScience
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
2001
Doxorubicin gradients in human breast cancer.
1999
Dispatcher-assisted cardiopulmonary resuscitation. Validation of efficacy.
1989
Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin
2007
Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents
1988
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
1991
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
1999
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
2002
Part 14: Pediatric Advanced Life Support
2010 Standout
Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin
2001
Regulation of Mammalian Autophagy in Physiology and Pathophysiology
2010 Standout
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
1996 StandoutScience
Works of P A Speth being referenced
Clinical Pharmacokinetics of Doxorubicin
1988
Investigation of the Role of Mononuclear Phagocytes in the Transportation of Doxorubicin-Containing Liposomes Into a Solid Tumor
1987
Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM)
1987
Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin
1986
Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated haematopoietic cells
1986
Evaluation of lay skills in cardiopulmonary resuscitation.
1985
Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion
1987
Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography
1985
Cellular and plasma pharmacokinetics of weekly 20-mg 4?-epi-adriamycin bolus injection in patients with advanced breast carcinoma
1986
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
1989